Download PDF
Semin Thromb Hemost 2012; 38(07): 735-741
DOI: 10.1055/s-0032-1326779
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Acquired Hemophilia A

Kathryn E. Webert
1   Canadian Blood Services, Medical Office, Hamilton, Ontario, Canada
2   Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
01 September 2012 (online)

    Permissions and Reprints

Abstract

Acquired hemophilia A is a rare, autoimmune disorder that is caused by autoantibodies that act as inhibitors to factor VIII. It is characterized by severe, unexpected bleeding that may be life-threatening. The incidence of acquired hemophilia A is ∼ 0.2 to 1.48 cases per 1 million individuals per year. Acquired hemophilia A has been associated with several clinical conditions including pregnancy, autoimmune or collagen vascular disorders, malignancies, drugs, respiratory disorders, and infections. However, in ∼ 50% of cases, no disease association is determined. Acquired hemophilia A should be suspected when a patient with no previous personal or family history of bleeding, presents with bleeding and an unexplained prolonged activated partial thromboplastin time (APTT) and other common causes of a prolonged APTT are ruled out. The treatment of acquired hemophilia A has two main goals: (1) to treat and/or prevent bleeding complications and (2) to eradicate the inhibitor. The recommended agents to be used for the treatment or prevention of bleeding in patients with acquired hemophilia A are the bypassing agents. Patients should be treated initially with corticosteroids, either alone or in combination with cyclophosphamide, to eradicate the inhibitor.

Keywords

acquired hemophilia A - inhibitors - bleeding
 

  • References

  • 1 Collins P, Macartney N, Davies R, Lees S, Giddings J, Majer R. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol 2004; 124 (1) 86-90
    CrossrefPubMedGoogle Scholar
  • 2 Knoebl P, Marco P, Baudo F , et al; EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10 (4) 622-631
    CrossrefPubMedGoogle Scholar
  • 3 Cohen AJ, Kessler CM. Acquired inhibitors. Baillieres Clin Haematol 1996; 9 (2) 331-354
    CrossrefPubMedGoogle Scholar
  • 4 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45 (3) 200-203
    PubMedGoogle Scholar
  • 5 Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97. Br J Haematol 1999; 104 (4) 909-914
    CrossrefPubMedGoogle Scholar
  • 6 Franchini M, Zaffanello M, Lippi G. Acquired hemophilia in pediatrics: a systematic review. Pediatr Blood Cancer 2010; 55 (4) 606-611
    CrossrefPubMedGoogle Scholar
  • 7 Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol 2005; 80 (1) 55-63
    CrossrefPubMedGoogle Scholar
  • 8 Collins PW, Hirsch S, Baglin TP , et al; UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109 (5) 1870-1877
    CrossrefPubMedGoogle Scholar
  • 9 The Association of Hemophilia Clinic Directors of Canada (AHCDC). A guide to the management of patients with inhibitors to factor VIII and factor IX. Toronto, Ontario, Canada: AHCDC; 2010. Available at: www.ahcdc.ca/documents/InhibitorGuide2010.pdf . Last accessed April 25, 2012
    PubMedGoogle Scholar
  • 10 Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol 2006; 81 (10) 768-773
    CrossrefPubMedGoogle Scholar
  • 11 Biggs R, Austen DE, Denson KW, Rizza CR, Borrett R. The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs. Br J Haematol 1972; 23 (2) 125-135
    CrossrefPubMedGoogle Scholar
  • 12 Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology (Am Soc Hematol Educ Program) 2006; 432-437
    PubMedGoogle Scholar
  • 13 Franchini M, Targher G, Montagnana M, Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta 2008; 395 (1-2) 14-18
    CrossrefPubMedGoogle Scholar
  • 14 Huth-Kühne A, Baudo F, Collins P , et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94 (4) 566-575
    CrossrefPubMedGoogle Scholar
  • 15 Kasper CK, Aledort L, Aronson D , et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34 (2) 612
    PubMedGoogle Scholar
  • 16 Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73 (2) 247-251
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982; 60 (5) 1103-1109
    PubMedGoogle Scholar
  • 18 Martin PG, Sukhu K, Chambers E, Giangrande PL. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Clin Lab Haematol 1999; 21 (2) 125-128
    CrossrefPubMedGoogle Scholar
  • 19 Sahud M, Zhukov O, Mo K, Popov J, Dlott J. False-positive results in ELISA-based anti FVIII antibody assay may occur with lupus anticoagulant and phospholipid antibodies. Haemophilia 2012; ; Epub ahead of print. doi: 10.111/j.1356-2516.2012.02781.x
    PubMedGoogle Scholar
  • 20 Collins P, Baudo F, Huth-Kühne A , et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes 2010; 3: 161
    CrossrefPubMedGoogle Scholar
  • 21 Collins PW. Management of acquired haemophilia A. J Thromb Haemost 2011; 9 (Suppl 1) 226-235
    PubMedGoogle Scholar
  • 22 Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147 (6) 1077-1081
    CrossrefPubMedGoogle Scholar
  • 23 FEIBA NF Anti-Inhibitor Coagulant Complex. Product monograph. Vienna, Austria; Baxter AG; 2011. Available at: www.baxter.ca/en/downloads/product_information/feiba_pm_en_070511.pdf . Last accessed April 25, 2012
    PubMedGoogle Scholar
  • 24 NiaStase RT Product monograph. Mississauga, Ontario, Canada; Novo Nordisk Canada, Inc.; 2010. Available at: www.novonordisk.ca/PDF_files/NiaStaseRTPMEnglish_2010-03-18.pdf . Last accessed April 25, 2012
    PubMed
  • 25 Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP , et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305 (13) 717-721
    CrossrefPubMedGoogle Scholar
  • 26 Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61 (1) 36-40
    PubMedGoogle Scholar
  • 27 Sultan Y, Loyer F. In vitro evaluation of factor VIII—bypassing activity of activated prothrombin complex concentrate, prothrombin complex concentrate, and factor VIIa in the plasma of patients with factor VIII inhibitors: thrombin generation test in the presence of collagen-activated platelets. J Lab Clin Med 1993; 121 (3) 444-452
    PubMedGoogle Scholar
  • 28 Barthels M. Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors. Thromb Res 1999; 95 (4, Suppl 1) S31-S38
    CrossrefPubMedGoogle Scholar
  • 29 Roberts HR. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia. Vox Sang 1999; 77 (Suppl 1) 38-41
    CrossrefPubMedGoogle Scholar
  • 30 Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999; 5 (Suppl 3) 25-32
    PubMedGoogle Scholar
  • 31 Abshire T. Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia. Semin Hematol 2008; 45 (2, Suppl 1) S3-S6
    CrossrefPubMedGoogle Scholar
  • 32 Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev 1993; 7 (2) 78-83
    CrossrefPubMedGoogle Scholar
  • 33 Papadaki HA, Xylouri I, Valatas W, Petinarakis J, Kontopoulou I, Eliopoulos GD. Severe acquired hemophilia A successfully treated with activated recombinant human factor VII. Ann Hematol 1998; 77 (3) 123-125
    CrossrefPubMedGoogle Scholar
  • 34 Hay CR, Ollier W, Pepper L , et al; UKHCDO Inhibitor Working Party. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost 1997; 77 (2) 234-237
    PubMedGoogle Scholar
  • 35 Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999; 82 (2) 531-539
    PubMedGoogle Scholar
  • 36 Ingerslev J, Sneppen O, Hvid I, Fredberg U, Kristensen HL, Sindet-Petersen S. Treatment of acute bleeding episodes with rFVIIa. Vox Sang 1999; 77 (Suppl 1) 42-46
    CrossrefPubMedGoogle Scholar
  • 37 Ingerslev J, Christiansen K, Calatzis A, Holm M, Sabroe Ebbesen L. Management and monitoring of recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1) S25-S30
    CrossrefPubMedGoogle Scholar
  • 38 Liebman HA, Chediak J, Fink KI, Galvez AG, Shah PC, Sham RL. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol 2000; 63 (3) 109-113
    CrossrefPubMedGoogle Scholar
  • 39 Jurlander B, Thim L, Klausen NK , et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001; 27 (4) 373-384
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42 (1) 114-124
    CrossrefPubMedGoogle Scholar
  • 41 Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia 2007; 13 (5) 451-461
    CrossrefPubMedGoogle Scholar
  • 42 Kessler CM, Ludlam CA ; International Acquired Hemophilia Study Group. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. Semin Hematol 1993; 30 (2, Suppl 1) 22-27
    PubMedGoogle Scholar
  • 43 Hay CR, Bolton-Maggs P. Porcine factor VIIIC in the management of patients with factor VIII inhibitors. Transfus Med Rev 1991; 5 (4) 293-299
    CrossrefPubMedGoogle Scholar
  • 44 Gatti L, Mannucci PM. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies. Thromb Haemost 1984; 51 (3) 379-384
    PubMedGoogle Scholar
  • 45 Kernoff PBA, Thomas ND, Lilley PA, Matthews KB, Goldman E, Tuddenham EG. Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood 1984; 63 (1) 31-41
    PubMedGoogle Scholar
  • 46 Brettler DB, Forsberg AD, Levine PH , et al. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med 1989; 149 (6) 1381-1385
    CrossrefPubMedGoogle Scholar
  • 47 Hay CRM. Innovative use of porcine factor VIII:C for immune tolerance induction. Am J Med 1991; 91 (5A) 27S-29S
    PubMedGoogle Scholar
  • 48 Franchini M, Lippi G. The use of desmopressin in acquired haemophilia A: a systematic review. Blood Transfus 2011; 9 (4) 377-382
    PubMedGoogle Scholar
  • 49 Francis JD, Leary T, Niblett DJ. Convulsions and respiratory arrest in association with desmopressin administration for the treatment of a bleeding tonsil in a child with borderline haemophilia. Acta Anaesthesiol Scand 1999; 43 (8) 870-873
    CrossrefPubMedGoogle Scholar
  • 50 Bertholini DM, Butler CS. Severe hyponatraemia secondary to desmopressin therapy in von Willebrand's disease. Anaesth Intensive Care 2000; 28 (2) 199-201
    PubMedGoogle Scholar
  • 51 Sunagawa T, Uezu Y, Kadena K, Tokuyama K, Kinjo F, Saito A. Successful treatment of a non-haemophilic patient with inhibitor to factor VIII by double-filtration plasmapheresis. Br J Haematol 1999; 104 (3) 465-467
    CrossrefPubMedGoogle Scholar
  • 52 Jansen M, Schmaldienst S, Banyai S , et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001; 112 (1) 91-97
    CrossrefPubMedGoogle Scholar
  • 53 Ogata H, Sakai S, Koiwa F , et al. Plasma exchange for acquired hemophilia: a case report. Ther Apher 1999; 3 (4) 320-322
    CrossrefPubMedGoogle Scholar
  • 54 Rivard GE, St Louis J, Lacroix S, Champagne M, Rock G. Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia 2003; 9 (6) 711-716
    CrossrefPubMedGoogle Scholar
  • 55 Seibert FS, Zidek W, Westhoff TH. Refractory acquired hemophilia: successful treatment by immunoadsorption with single-use columns. Ther Apher Dial 2011; 15 (3) 336-337
    CrossrefPubMedGoogle Scholar
  • 56 Guillet B, Kriaa F, Huysse MG , et al. Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia. Br J Haematol 2001; 114 (4) 837-844
    CrossrefPubMedGoogle Scholar
  • 57 Collins P, Baudo F, Knoebl P , et al. Immunosuppression for acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; ; Epub ahead of print. doi 10.1182/blood-2012-02-409185
    PubMedGoogle Scholar
  • 58 Green D, Rademaker AW, Briët E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993; 70 (5) 753-757
    PubMedGoogle Scholar
  • 59 Green D. Oral immunosuppressive therapy for acquired hemophilia. Ann Intern Med 1998; 128 (4) 325
    PubMedGoogle Scholar
  • 60 Shaffer LG, Phillips MD. Successful treatment of acquired hemophilia with oral immunosuppressive therapy. Ann Intern Med 1997; 127 (3) 206-209
    CrossrefPubMedGoogle Scholar
  • 61 Reff ME, Carner K, Chambers KS , et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83 (2) 435-445
    PubMedGoogle Scholar
  • 62 Byrd JC, Kitada S, Flinn IW , et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99 (3) 1038-1043
    CrossrefPubMedGoogle Scholar
  • 63 Aggarwal A, Grewal R, Green RJ , et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia 2005; 11 (1) 13-19
    CrossrefPubMedGoogle Scholar
  • 64 Boles JC, Key NS, Kasthuri R, Ma AD. Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia. J Thromb Haemost 2011; 9 (7) 1429-1431
    CrossrefPubMedGoogle Scholar
  • 65 Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103 (12) 4424-4428
    CrossrefPubMedGoogle Scholar
  • 66 Wiestner A, Cho HJ, Asch AS , et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100 (9) 3426-3428
    CrossrefPubMedGoogle Scholar
  • 67 Kain S, Copeland TS, Leahy MF. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). Br J Haematol 2002; 119 (2) 578
    CrossrefPubMedGoogle Scholar
  • 68 Abdallah A, Coghlan DW, Duncan EM, Chunilal SD, Lloyd JV. Rituximab-induced long-term remission in patients with refractory acquired hemophilia. J Thromb Haemost 2005; 3 (11) 2589-2590
    CrossrefPubMedGoogle Scholar
  • 69 Jy W, Gagliano-DeCesare T, Kett DH , et al. Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab. Acta Haematol 2003; 109 (4) 206-208
    CrossrefPubMedGoogle Scholar
  • 70 Holme PA, Brosstad F, Tjønnfjord GE. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 2005; 11 (5) 510-515
    CrossrefPubMedGoogle Scholar
  • 71 Söhngen D, Specker C, Bach D , et al. Acquired factor VIII inhibitors in nonhemophilic patients. Ann Hematol 1997; 74 (2) 89-93
    CrossrefPubMedGoogle Scholar
  • 72 Lian EC, Larcada AF, Chiu AY. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989; 110 (10) 774-778
    CrossrefPubMedGoogle Scholar
  • 73 Eisert S, Mosler K, Laws HJ, Göbel U. Successful use of mycophenolate mofetil and prednisone in a 14-year-old girl with acquired hemophilia A. Thromb Haemost 2005; 93 (4) 792-793
    PubMedGoogle Scholar
  • 74 Schulman S, Langevitz P, Livneh A, Mortinowitz U, Seligsohn U, Varon D. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost 1996; 76 (3) 344-346
    PubMedGoogle Scholar
  • 75 Brox AG, Laryea H, Pelletier M. Successful treatment of acquired factor VIII inhibitors with cyclosporin. Am J Hematol 1998; 57 (1) 87-88
    CrossrefPubMedGoogle Scholar
  • 76 Petrovic M, Derom E, Baele G. Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies. Haematologica 2000; 85 (8) 895-896
    PubMedGoogle Scholar
  • 77 Saxena R, Mishra DK, Kashyap R, Choudhry VP, Mahapatra M, Bhargava M. Acquired haemophilia - a study of ten cases. Haemophilia 2000; 6 (2) 78-83
    CrossrefPubMedGoogle Scholar
  • 78 Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood 2008; 112 (2) 250-255
    CrossrefPubMedGoogle Scholar
  • 79 Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007; 5 (5) 893-900
    CrossrefPubMedGoogle Scholar
  • 80 Shurafa M, Raman S, Wollner I. Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma. Am J Hematol 1995; 50 (2) 149-150
    PubMedGoogle Scholar
  • 81 Solymoss S. Postpartum acquired factor VIII inhibitors: results of a survey. Am J Hematol 1998; 59 (1) 1-4
    CrossrefPubMedGoogle Scholar
  • 82 Baudo F, de Cataldo F ; Italian Association of Haemophilia Centres (AICE): Register of acquired factor VIII inhibitors (RIIA). Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. BJOG 2003; 110 (3) 311-314
    CrossrefPubMedGoogle Scholar
  • 83 Kessler CM, Acs P, Mariani G. Hemostasis and thrombosis: basic principles and clinical practice. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, , eds. LWW Medical Book Collection. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 1061-1084
    Google Scholar
  • 84 Hauser I, Schneider B, Lechner K. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost 1995; 73 (1) 1-5
    PubMedGoogle Scholar
  • 85 Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121 (1) 21-35
    CrossrefPubMedGoogle Scholar
  • 86 Tagariello G, Sartori R, Radossi P, Gandini G, Franchini M. Intensive blood transfusion support in acquired hemophilia A. Ann Hematol 2007; 86 (3) 229-230
    CrossrefPubMedGoogle Scholar